📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Alexion

1.1 - Company Overview

Alexion Logo

Alexion

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biologic therapies for severe, life-threatening diseases, including hematologic, kidney and neurologic conditions, transplant rejection, cancer and autoimmune disorders; portfolio includes SOLIRIS (PNH, aHUS, NMOSD), ULTOMIRIS (PNH, aHUS), STRENSIQ (HPP) and KANUMA (LAL-D), plus patient support and managed access programs.

Products and services

  • SOLIRIS (eculizumab): Biologic medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti‑aquaporin‑4 (AQP4) antibody‑positive neuromyelitis optica spectrum disorder (NMOSD)
  • STRENSIQ (asfotase alfa): Enzyme replacement therapy for patients with hypophosphatasia (HPP), a rare metabolic bone disease, delivering a targeted therapeutic approach to this severe condition
  • ULTOMIRIS (ravulizumab-cwvz): Long-acting C5 complement inhibitor indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), delivering sustained treatment across both conditions

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Alexion

Apexigen Logo

Apexigen

HQ: United States Website
  • Description: Provider of clinical-stage immuno-oncology antibody therapeutics for cancer, including sotigalimab (PYX-107), a Phase 2 CD40 agonist with demonstrated anti-cancer activity in patients who have progressed on PD-(L)1 inhibitors, and the APXiMAB platform for generating novel antibodies optimized for targeted payload delivery in antibody-drug conjugates.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Apexigen company profile →
Dyne Therapeutics Logo

Dyne Therapeutics

HQ: United States Website
  • Description: Provider of targeted therapies for serious muscle diseases, including DYNE-101 for myotonic dystrophy type 1 to reduce mutant DMPK RNA, DYNE-251 for Duchenne muscular dystrophy amenable to exon 51 skipping to enable truncated, functional dystrophin, and DYNE-301 for facioscapulohumeral muscular dystrophy by reducing DUX4 expression; uses its FORCE platform to develop targeted oligonucleotide therapeutics and conducts clinical trials.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Dyne Therapeutics company profile →
Y-mAbs Therapeutics Logo

Y-mAbs Therapeutics

HQ: United States Website
  • Description: Provider of innovative cancer treatments and support services, including FDA-approved DANYELZA (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma in bone or bone marrow; clinical trials for investigational therapies (naxitamab, omburtamab, GD2-SADA); expanded access programs; Y-mAbs Connect for access, insurance and financial support; and patient and family resources.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Y-mAbs Therapeutics company profile →
Akari Therapeutics Logo

Akari Therapeutics

HQ: United Kingdom Website
  • Description: Provider of clinical-stage therapeutics focused on development and commercialization of innovative treatments, including nomacopan, a bispecific recombinant inhibitor targeting complement C5 and LTB4 for autoimmune and inflammatory diseases; a Phase 3 HSCT-TMA program for pediatric and adult transplant-related thrombotic microangiopathy; and PAS-nomacopan, a long-acting candidate for geographic atrophy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Akari Therapeutics company profile →
NovAccess Global Logo

NovAccess Global

HQ: United States Website
  • Description: Provider of cancer and neurological disease immunotherapies and diagnostics, combining clinical-stage asset acquisition with medical assets in the market. Through StemVax Therapeutics, develops dendritic cell-based immunotherapies for glioblastoma with TLR adjuvants, and leverages AI, bio-sensing, and blockchain-powered AI to advance diagnostics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NovAccess Global company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Alexion

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Alexion

2.2 - Growth funds investing in similar companies to Alexion

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Alexion

4.2 - Public trading comparable groups for Alexion

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Alexion

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Alexion

What does Alexion do?

Alexion is a provider of biologic therapies for severe, life-threatening diseases, including hematologic, kidney and neurologic conditions, transplant rejection, cancer and autoimmune disorders; portfolio includes SOLIRIS (PNH, aHUS, NMOSD), ULTOMIRIS (PNH, aHUS), STRENSIQ (HPP) and KANUMA (LAL-D), plus patient support and managed access programs.

Who are Alexion's competitors?

Alexion's competitors and similar companies include Apexigen, Dyne Therapeutics, Y-mAbs Therapeutics, Akari Therapeutics, and NovAccess Global.

Where is Alexion headquartered?

Alexion is headquartered in United States.

How many employees does Alexion have?

Alexion has 1,000 employees 🔒.

When was Alexion founded?

Alexion was founded in 2010 🔒.

What sector and industry vertical is Alexion in?

Alexion is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Alexion

Who are the top strategic acquirers in Alexion's sector and industry

Top strategic M&A buyers and acquirers in Alexion's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Alexion?

Top strategic M&A buyers groups and sectors for Alexion include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Alexion's sector and industry vertical

Which are the top PE firms investing in Alexion's sector and industry vertical?

Top PE firms investing in Alexion's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Alexion's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Alexion's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Alexion's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Alexion include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Alexion's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Alexion?

The key public trading comparables and valuation benchmarks for Alexion include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Alexion for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Alexion with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Alexion's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Alexion with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Alexion's' sector and industry vertical?

Access recent funding rounds and capital raises in Alexion's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Alexion